T1	Participants 471 595	non-and-low response children in group A (before booster), group B (after 1 dose booster) and group C (after 3 dose booster)
T2	Participants 219 450	Non-and-low response infants born in 2004 2005 administered 3 doses of HepB at 0, 1, 6 months in Guangzhou, Beijing and Zhejiang were divided into 4 groups randomly, and boosted 3 dose of 4 different types of HepB at 0, 1, 6 months
